[go: up one dir, main page]

WO2002079504A3 - Neotic and endoapoptotic cells and detection of neosis and endoapoptosis - Google Patents

Neotic and endoapoptotic cells and detection of neosis and endoapoptosis Download PDF

Info

Publication number
WO2002079504A3
WO2002079504A3 PCT/CA2002/000419 CA0200419W WO02079504A3 WO 2002079504 A3 WO2002079504 A3 WO 2002079504A3 CA 0200419 W CA0200419 W CA 0200419W WO 02079504 A3 WO02079504 A3 WO 02079504A3
Authority
WO
WIPO (PCT)
Prior art keywords
neosis
cells
neotic
endoapoptotic
endoapoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2002/000419
Other languages
French (fr)
Other versions
WO2002079504A9 (en
WO2002079504A2 (en
Inventor
Rengaswami Rajaraman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalhousie University
Original Assignee
Dalhousie University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalhousie University filed Critical Dalhousie University
Priority to AU2002242552A priority Critical patent/AU2002242552A1/en
Publication of WO2002079504A2 publication Critical patent/WO2002079504A2/en
Publication of WO2002079504A9 publication Critical patent/WO2002079504A9/en
Publication of WO2002079504A3 publication Critical patent/WO2002079504A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Described herein are methods for isolating cells involved in neosis, cells or tissue compositions having an enriched populations of cells involved in neosis, methods of identifying compounds that modulates neosis, and tumor progression diagnostic methods.
PCT/CA2002/000419 2001-03-30 2002-03-28 Neotic and endoapoptotic cells and detection of neosis and endoapoptosis Ceased WO2002079504A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002242552A AU2002242552A1 (en) 2001-03-30 2002-03-28 Neotic and endoapoptotic cells and detection of neosis and endoapoptosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82369201A 2001-03-30 2001-03-30
US09/823,692 2001-03-30

Publications (3)

Publication Number Publication Date
WO2002079504A2 WO2002079504A2 (en) 2002-10-10
WO2002079504A9 WO2002079504A9 (en) 2002-12-05
WO2002079504A3 true WO2002079504A3 (en) 2003-08-21

Family

ID=25239431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000419 Ceased WO2002079504A2 (en) 2001-03-30 2002-03-28 Neotic and endoapoptotic cells and detection of neosis and endoapoptosis

Country Status (2)

Country Link
AU (1) AU2002242552A1 (en)
WO (1) WO2002079504A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020054A1 (en) * 1994-01-21 1995-07-27 Coulter Corporation Solid tumor analysis by multiparametric flow cytometry
CA2223226A1 (en) * 1996-12-02 1998-06-02 Dalhousie University Method for cancer screening
WO1999049774A2 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Methods for the diagnosis and treatment of lung cancer
WO2000034757A1 (en) * 1998-12-10 2000-06-15 The Government Of The Unites States Of America Represented By The Secretary, Department Of Health And Human Services Designs for non-contact laser capture microdissection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020054A1 (en) * 1994-01-21 1995-07-27 Coulter Corporation Solid tumor analysis by multiparametric flow cytometry
CA2223226A1 (en) * 1996-12-02 1998-06-02 Dalhousie University Method for cancer screening
US6245501B1 (en) * 1996-12-02 2001-06-12 Dalhousie University Method for cancer screening
WO1999049774A2 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Methods for the diagnosis and treatment of lung cancer
WO2000034757A1 (en) * 1998-12-10 2000-06-15 The Government Of The Unites States Of America Represented By The Secretary, Department Of Health And Human Services Designs for non-contact laser capture microdissection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PASQUALI C ET AL: "Subcellular fractionation, electromigration analysis and mapping of organelles", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL APPLICATIONS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 722, no. 1-2, 5 February 1999 (1999-02-05), pages 89 - 102, XP004156207, ISSN: 0378-4347 *
RAJARAMAN R ET AL: "Endoapoptosis: A novel form of apoptosis without cell death and its role in neoplasia.", MOLECULAR BIOLOGY OF THE CELL, vol. 7, no. SUPPL., 1996, Annual Meeting of the 6th International Congress on Cell Biology and the 36th American Society for Cell Biology;San Francisco, California, USA; December 7-11, 1996, pages 519A, XP009011929, ISSN: 1059-1524 *

Also Published As

Publication number Publication date
AU2002242552A1 (en) 2002-10-15
WO2002079504A9 (en) 2002-12-05
WO2002079504A2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP2230319A3 (en) Gene expression markers for breast cancer prognosis
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1700120A4 (en) Marker for neuromyelitis optica
WO2005009928A3 (en) Preparation and use of alkylating agents
MXPA01011182A (en) Methods, compositions and kits for biological indicator of sterilization.
DE69938192D1 (en) Imidazonaphthyridine
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
WO2002018954A3 (en) Inhibition of cmv infection and dissemination
WO2002092024A3 (en) Compounds and methods for inhibiting axillary malodour
WO2003084384A3 (en) Diagnosis of flavivirus infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 25-67, DESCRIPTION, REPLACED BY NEW PAGES 25-68; PAGES 68-74, CLAIMS, REPLACED BY NEW PAGES 69-75; PAGES 1/34-34/34, DRAWINGS, REPLACED BY NEW PAGES 1/37-37/37; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP